IDTA Quote, Financials, Valuation and Earnings

InMode Ltd. has a net margin of 18.62% compared to Identa Corp.'s net margin of 26.02%. Identa Corp.'s return on equity of -8.67% beat InMode Ltd.'s return on equity of 14.27%.

Identa Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand InMode Ltd. has an analysts' consensus of $16.80 which suggests that it could grow by 11.3%. Given that InMode Ltd. has higher upside potential than Identa Corp., analysts believe InMode Ltd. is more attractive than Identa Corp..

Identa Corp. has a beta of 0.551, which suggesting that the stock is 44.895% less volatile than S&P 500. In comparison InMode Ltd. has a beta of 2.187, suggesting its more volatile than the S&P 500 by 118.719%.

Identa Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InMode Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Identa Corp. pays -- of its earnings as a dividend. InMode Ltd. pays out -- of its earnings as a dividend.

Identa Corp. quarterly revenues are $427.5K, which are smaller than InMode Ltd. quarterly revenues of $103.9M. Identa Corp.'s net income of $79.6K is lower than InMode Ltd.'s net income of $27M. Notably, Identa Corp.'s price-to-earnings ratio is 7.51x while InMode Ltd.'s PE ratio is 10.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Identa Corp. is 1.06x versus 2.66x for InMode Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

IR-Med, Inc. has a net margin of 18.62% compared to Identa Corp.'s net margin of --. Identa Corp.'s return on equity of -8.67% beat IR-Med, Inc.'s return on equity of --.

Identa Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand IR-Med, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Identa Corp. has higher upside potential than IR-Med, Inc., analysts believe Identa Corp. is more attractive than IR-Med, Inc..

Identa Corp. has a beta of 0.551, which suggesting that the stock is 44.895% less volatile than S&P 500. In comparison IR-Med, Inc. has a beta of 2.937, suggesting its more volatile than the S&P 500 by 193.663%.

Identa Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IR-Med, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Identa Corp. pays -- of its earnings as a dividend. IR-Med, Inc. pays out -- of its earnings as a dividend.

Identa Corp. quarterly revenues are $427.5K, which are larger than IR-Med, Inc. quarterly revenues of --. Identa Corp.'s net income of $79.6K is higher than IR-Med, Inc.'s net income of -$701K. Notably, Identa Corp.'s price-to-earnings ratio is 7.51x while IR-Med, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Identa Corp. is 1.06x versus -- for IR-Med, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pluri, Inc. has a net margin of 18.62% compared to Identa Corp.'s net margin of -3470.71%. Identa Corp.'s return on equity of -8.67% beat Pluri, Inc.'s return on equity of -5662.45%.

Identa Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 226.09%. Given that Pluri, Inc. has higher upside potential than Identa Corp., analysts believe Pluri, Inc. is more attractive than Identa Corp..

Identa Corp. has a beta of 0.551, which suggesting that the stock is 44.895% less volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.181%.

Identa Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Identa Corp. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.

Identa Corp. quarterly revenues are $427.5K, which are larger than Pluri, Inc. quarterly revenues of $198K. Identa Corp.'s net income of $79.6K is higher than Pluri, Inc.'s net income of -$6.9M. Notably, Identa Corp.'s price-to-earnings ratio is 7.51x while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Identa Corp. is 1.06x versus 22.48x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Raphael Pharmaceutical, Inc. has a net margin of 18.62% compared to Identa Corp.'s net margin of --. Identa Corp.'s return on equity of -8.67% beat Raphael Pharmaceutical, Inc.'s return on equity of --.

Identa Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Raphael Pharmaceutical, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Identa Corp. has higher upside potential than Raphael Pharmaceutical, Inc., analysts believe Identa Corp. is more attractive than Raphael Pharmaceutical, Inc..

Identa Corp. has a beta of 0.551, which suggesting that the stock is 44.895% less volatile than S&P 500. In comparison Raphael Pharmaceutical, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Identa Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Raphael Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Identa Corp. pays -- of its earnings as a dividend. Raphael Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Identa Corp. quarterly revenues are $427.5K, which are larger than Raphael Pharmaceutical, Inc. quarterly revenues of --. Identa Corp.'s net income of $79.6K is higher than Raphael Pharmaceutical, Inc.'s net income of -$255K. Notably, Identa Corp.'s price-to-earnings ratio is 7.51x while Raphael Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Identa Corp. is 1.06x versus -- for Raphael Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.